Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by V Square Quantitative Management LLC

V Square Quantitative Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 356.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,692 shares of the biopharmaceutical company's stock after purchasing an additional 1,321 shares during the period. V Square Quantitative Management LLC's holdings in Alnylam Pharmaceuticals were worth $552,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALNY. Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $243,000. Wealth Enhancement Advisory Services LLC increased its holdings in Alnylam Pharmaceuticals by 94.7% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 12,566 shares of the biopharmaceutical company's stock valued at $2,957,000 after buying an additional 6,112 shares in the last quarter. Versant Capital Management Inc increased its holdings in Alnylam Pharmaceuticals by 76.8% in the first quarter. Versant Capital Management Inc now owns 336 shares of the biopharmaceutical company's stock valued at $91,000 after buying an additional 146 shares in the last quarter. GAMMA Investing LLC increased its holdings in Alnylam Pharmaceuticals by 30,759.4% in the first quarter. GAMMA Investing LLC now owns 166,332 shares of the biopharmaceutical company's stock valued at $44,913,000 after buying an additional 165,793 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Alnylam Pharmaceuticals by 1.0% in the first quarter. Rhumbline Advisers now owns 181,463 shares of the biopharmaceutical company's stock valued at $48,999,000 after buying an additional 1,885 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 6,979 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the completion of the sale, the chief executive officer owned 56,221 shares of the company's stock, valued at approximately $25,483,292.67. This represents a 11.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Colleen F. Reitan sold 18,000 shares of the company's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the sale, the director directly owned 775 shares of the company's stock, valued at approximately $362,390. This represents a 95.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 75,594 shares of company stock worth $33,968,256 in the last 90 days. 1.20% of the stock is owned by insiders.

Analysts Set New Price Targets

ALNY has been the subject of a number of recent analyst reports. BMO Capital Markets lifted their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an "outperform" rating in a report on Friday, September 5th. Oppenheimer raised shares of Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 price objective for the company in a report on Monday, August 4th. Bank of America lifted their price objective on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a "buy" rating in a report on Wednesday, September 17th. Wolfe Research raised shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a report on Monday, August 4th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $439.58.

Alnylam Pharmaceuticals Stock Up 1.9%

ALNY stock opened at $456.00 on Wednesday. The stock has a market capitalization of $59.77 billion, a P/E ratio of -184.62 and a beta of 0.32. The firm has a 50-day simple moving average of $433.66 and a 200-day simple moving average of $334.99. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million during the quarter, compared to analysts' expectations of $633.54 million. During the same quarter in the prior year, the company earned ($0.13) EPS. Alnylam Pharmaceuticals's revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.